Pictet Asset Management Holding SA Takes Position in Savara Inc. $SVRA

Pictet Asset Management Holding SA purchased a new position in shares of Savara Inc. (NASDAQ:SVRA) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,275,381 shares of the company’s stock, valued at approximately $12,424,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Rhumbline Advisers boosted its holdings in Savara by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock valued at $388,000 after purchasing an additional 16,634 shares during the period. Prudential Financial Inc. bought a new position in shares of Savara during the second quarter worth approximately $30,000. XTX Topco Ltd acquired a new stake in shares of Savara in the second quarter valued at approximately $201,000. Invesco Ltd. raised its position in shares of Savara by 35.4% in the second quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock valued at $276,000 after buying an additional 31,633 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Savara by 14.2% in the second quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after buying an additional 6,449 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Up 2.6%

Shares of SVRA opened at $6.22 on Friday. Savara Inc. has a one year low of $2.10 and a one year high of $7.01. The company has a market cap of $1.27 billion, a P/E ratio of -11.11 and a beta of 0.24. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. The firm has a 50 day simple moving average of $5.30 and a two-hundred day simple moving average of $5.56.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Research analysts forecast that Savara Inc. will post -0.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on SVRA. Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. William Blair set a $10.00 price objective on Savara in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. Oppenheimer assumed coverage on Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Savara in a research report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.14.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.